Mississippi Cancer Registry Deirdre B. Rogers, MS Director Mississippi Cancer Registry.

Slides:



Advertisements
Similar presentations
Consolidated User Story 1: Chronic Diseases (cancer, occupational health) Chronic Diseases, Outpatient Flow Patient, Provider/Physician, Laboratory, PH.
Advertisements

Cancer Registry Follow-up How we do it
Instructions and Reporting Requirements Module 3 Electronic Reporting For Facilities March 2014 North Carolina Central Cancer Registry State Center for.
Instructions and Reporting Requirements Module 11 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry.
Instructions and Reporting Requirements Module 2 Electronic Reporting For Facilities March 2014 North Carolina Central Cancer Registry State Center for.
Hematopoietic and Lymphoid Neoplasm Project. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
STAGING MCR Staff Show Me Healthy Women March 27, 2008 Supported by a Cooperative Agreement between DHSS and the Centers for Disease Control and Prevention.
Nadya Dimitrova Marieta Petkova. 13 Regional cancer registries BNCR: -Established in 1952; cases a year; million population;
SQUAMOUS CELL CARCINOMA
ICD-10 Getting There….. Pathology. What Physicians Need To Know Claims for ambulatory and physician services provided on or after 10/1/2015 must use ICD-10-CM.
TRAM Educational Conference September 19, 2014 Meritus Medical Center 1.
Directly Coded Summary Stage
Use Case 7 IHE Profiles & Actors Care Theme: Leveraging Healthcare Registries in Care Delivery Use Case: Optimizing Cancer Care Coordination Leveraging.
Cervical Cancer. Cervix Lower part of the uterus Lower part of the uterus Connects the body of the uterus to the vagina (birth canal) Connects the body.
Instructions and Reporting Requirements Appendix B Electronic Reporting For Dermatology Physician Practices March 2014 North Carolina Central Cancer Registry.
Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.
Finding Cases for Low Volume Hospitals This training is provided by the Missouri Cancer Registry MCR gratefully acknowledges Louanne Currence, RHIT, CTR.
Terminology of Neoplasms and Tumors  Neoplasm - new growth  Tumor - swelling or neoplasm  Leukemia - malignant disease of bone marrow  Hematoma -
Finding Cases for Low Volume Hospitals This training is provided by the Missouri Cancer Registry MCR gratefully acknowledges Louanne Currence, RHIT, CTR.
Quang Truong Mr. Kashub 2nd Session
SC430 Molecular Cell Biology
1 MP/H Coding Rules General Instructions MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
Using Abbreviated Text Arkansas Central Cancer Registry Annual Education Meeting Alfreda Smith, CTR Charlette Bellefeuille, CTR June 2, 2005.
2010 Hematopoietic and Lymphoid Neoplasm Project Registry Operations and the SEER Program.
Instructions and Reporting Requirements Appendix B Electronic Reporting For Facilities March 2014 North Carolina Central Cancer Registry State Center.
Casefinding & Follow-Up Dolores E. McCord, RHIT, CTR Piedmont Hospital Atlanta, Georgia.
Cancer Staging.
Lung Cancer Emily Cauchon Katie Reeves Emily Cauchon Katie Reeves.
Endometrial Carcinoma
NATIONAL CANCER REGISTRY IRELAND. Basic registration dataset Patient dataCancer dataTreatment and follow up registration numbertumour idtreatment id year.
Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.
MCR and WebPlus: Melanoma Reporting Nancy Cole, Missouri Cancer Registry.
Timeliness of Cancer Registry Reporting Ali Johnson, CTR Vermont Cancer Registry Vermont Explor Annual Data Meeting May 1, 2006.
CASEFINDING Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center.
What’s the Diff? Sue C. Vest, CTR Missouri Cancer Registry This project was supported in part by a cooperative agreement between the Centers for Disease.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Principles of Surgical Oncology Done by : 428 surgery team surgery team.
Retention of Medical Records Law April 2002 Source: records-retention0402.shtml
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Chapter 6 Cancer. Frequency and Significance Cancer is the 2 nd leading cause of death in the United States Obviously, the term cancer covers many types.
Say Goodbye to Paper: Web-Based Reporting is Here! Iris Zachary, MS, CTR, Missouri Cancer Registry.
Pathology.
Treatment Patterns in the Management of Prostate Cancer: Lessons Learned from the Florida Cancer Data System Vonetta L. Williams, PhD, MPH, CTR June 23,
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
Vicki LaRue, CTR KCR Abstractor’s Training February 12,
*Be brief, yet thorough enough to allow recoding of the data fields from the text only! * Use accepted abbreviations from Abstractor’s Manual Appendix.
Everybody’s Got A Story……….. Text tells “the story” in readable language that supports the coding Accurate, concise summary of the patient’s cancer.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
BY FRANCES ROSS, CTR PRESENTED AT THE NAACCR ANNUAL CONFERENCE JUNE, 2008 Record Consolidation Test with the 2007 Multiple Primary/Histology Rules.
Integrating Central and Hospital Registries To Improve Timeliness and Data Quality (The Central Cancer Registry as a Hub for Data Exchange) David Rousseau,
Rhode Island Cancer Registry Internship Training Program David Rousseau, BS Director, CIS Hospital Association of Rhode Island Rhode Island Cancer Registry.
Linking Electronic Health Records Across Institutions to Understand Why Women Seek Care at Multiple Sites for Breast Cancer Caroline A. Thompson, PhD,
1 Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.
Presented at the NAACCR Annual Conference Quebec City June 22, 2010.
Electronic CAP Cancer Checklists and Cancer Registries – A Pilot Project 2009 NAACCR Conference Ken Gerlach, MPH, CTR Castine Verrill, MS, CTR CDC-National.
Treatment Capture from Follow Back to Oncology Offices by Frances Ross Presented at the 2013 NAACCR Annual Conference Austin, TX.
Kidney Cancer – All You Need to Know!
The Role of the HCC Cancer Registry in Facilitating Cancer Research Linda Cope, CTR HCC Registry Coordinator
Non-hospital Cancer Reporting Guidelines and Tips
Optimizing your EMR in the Cancer Registry
Cancer Reporting Changes for 2017 and 2018
Quality Control Abstract Visual Review Process
Creating the perfect text…
Surgical Cancer Treatment
SEER Case Consolidation Study: Design & Objective
Surgical Cancer Treatment
Treatment Overview: The Multidisciplinary Team
Presentation transcript:

Mississippi Cancer Registry Deirdre B. Rogers, MS Director Mississippi Cancer Registry

MCR Staff Debra Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research and Registry Deirdre Rogers, MS Director, Mississippi Cancer Registry Kathryn Sheppard, RHIA, CTR Cancer Registry Coordinator Donna Gooch Cancer Registry Coordinator

MCR Staff La’Tawnya Roby Cancer Registry Coordinator Carla Triplett, RHIT Cancer Registry Coordinator Kristy Brister, RHIA Cancer Registry Coordinator Ramona Corkern, RHIA, CCS HIM Systems Analyst

MCR History Mississippi Legislature authorized Mississippi State Department of Health to establish a central population-based incidence cancer registry Data collection began January – Program was relocated to the University of Mississippi Medical Center

Reporting Cases Report cases monthly –If you upload your file, please zip the file before uploading –If you enter data directly into HRN and your patient information is automatically filled in for you, please mark the check box next to “Reconcile Hold.” Send corrections on paper. Write “Correction” at the top and highlight the corrected item(s). Do not resend the case electronically

Reportable Cases Refer to your list of reportable cases. Cases diagnosed on or after January 1, 1996 Diagnosed and/or treated at your facility Pathology only cases read by pathologists must be reported (i.e., interpretation for another facility; sent for a second opinion; procedure elsewhere sent to pathology).

Physician cases VAIN III, VIN III, AIN III (Not required by ACoS; Required by NPCR/MCR) Benign and borderline brain tumors (Behavior codes 0 & 1) effective January 1, 2004 Be sure to refer to the list of ambiguous terms when determining if reportable.

Do Not Report History only of cancer cases Basal cell and squamous cell carcinomas of the skin PIN III CIN III CIS of cervix

Flow of Data through the MCR Data Reported by the Facilities –Hospitals with software – Upload into HRN –Facilities with >25 cases and no software Enter directly into HRN –Facilities with <25 cases – Paper abstracts entered into HRN by MCR staff Data is matched within the system. Multiple reports for a cancer are consolidated. Quality Control is performed on data.

Flow of Data through the MCR Follow-back is conducted on all pathology-only (class 7) cases. Interstate data exchange is conducted biennially. All data matched with the mortality data from MSDH Vital Records. –Vital status, cause of death and date of death recorded. –Follow-up conducted on all cancer deaths with no matching incidence record.

Flow of Data through the MCR Data is submitted to the CDC’s National Program of Cancer Registries in January of each year. Data is analyzed and published.

Other MCR Activities Training and Technical Assistance Audits

Importance of Text Text is the most important part of the record for the MCR We all make mistakes. Text helps correct the mistakes. Record consolidation can be impossible without text. The MCR cannot access the medical records, so we use the text fields in place of a medical record.

Physical Exam Age, sex, race/ethnicity Past medical/social history Symptoms Tumor location and size Palpable lymph nodes Impression (when stated and pertains to cancer diagnosis)

Laboratory Type of lab test/tissue specimen(s) Record both positive and negative findings – positive first Serum and urine electrophoresis, special studies, etc. Tumor markers

Pathology Date(s) of procedure(s) Pathology report number Type of tissue specimen(s) Tumor type and grade (site and histology) Gross tumor size Extent of tumor spread Involvement of surgical margins Number of lymph nodes involved and/or examined Note if path report is a slide review or second opinion Record any additional comments from the pathologist, including differential diagnoses considered and any ruled out or favored.

Scopes, X-rays, and Scans Date of procedure Tumor location Tumor size Types of lymph nodes, if given; number of lymph nodes involved and examined Distant disease or metastasis

Operations Dates and descriptions of biopsies and all other surgical procedures from which staging information was derived. Number of lymph nodes removed and/or examined Size of tumor removed Documentation of residual tumor Evidence of invasion of surrounding area.

Staging Organs involved by direct extension Size of tumor Status of margins Number and sites of positive lymph nodes Site(s) of distant metastasis

Place of Diagnosis Fill in the name of the facility where the patient was diagnosed. If your facility diagnosed the patient, then put your facility’s name in this field.

Primary Site Title and Morphology Title Please do not skip these fields Be specific –Example: Primary Site Title: Rt Lower Lobe Lung Morphology Title: Squamous Cell Carcinoma

Remarks Document any information that would be beneficial –Names and contact information of other treating physicians or healthcare facilities –Additional information not stated in the other text fields

Surgery, Radiation, Chemotherapy, Hormone, BRM, or Other Therapy Treatment date(s) Where treatment was given Type of treatment Other text, such as, patient discontinued after five cycles or unknown if therapy given

And Finally… Avoid Unknowns (i.e., summary stage, birth date, race, etc.) If you need help, please contact the MCR at